Phase I/II Study of Combination Therapy With MRA (Tocilizumab) and Gemcitabine for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Latest Information Update: 20 Nov 2018
At a glance
- Drugs Gemcitabine (Primary) ; Tocilizumab (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 27 May 2016 New trial record